IsomAb is a pre-clinical stage company with Proof-of-Concept data, in two animal models, and an ambitious plan to take its first product into the clinic by 2026.
DATE FIRST INVESTED
IsomAb is taking a different approach to identify, evaluate and develop isoform specific antibodies to treat disease where patients currently have limited treatment options.
IsomAb is developing isoform specific, humanised IgG1 based antibodies and it has identified, using a combined bioinformatics/knowledge-based platform approach, its first antibody against Vascular Endothelial Growth Factor A (VEGF-A). Our strategy utilises an antibody to specifically inhibit the VEGF-A165b isoforms; based on 20 years of research, the evidence shows this isoform is key to preventing collateral vessel formation in ischemic diseases.